GlobeStar Therapeutics (GSTC) Stock Price, News & Analysis

Company Overview

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0012
• Volume: 5.59 million shs
• Average Volume: 3.22 million shs
• Market Capitalization: $248,221.20
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GSTC Stock Analysis - Frequently Asked Questions

How have GSTC shares performed this year?

GlobeStar Therapeutics' stock was trading at $0.0003 on January 1st, 2025. Since then, GSTC shares have decreased by 33.3% and is now trading at $0.0002.
View the best growth stocks for 2025 here.

How do I buy shares of GlobeStar Therapeutics?

Shares of GSTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GlobeStar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlobeStar Therapeutics investors own include Arrival (ARVL), Cosmos Health (COSM), COMSovereign (COMS), Good Hemp (GHMP), Meta Materials (MMTLP), Palisade Bio (PALI) and Sintx Technologies (SINT).

Company Calendar

• Today: 4/03/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GSTC
• CIK: 1502152
• Web: angiosoma.com
• Phone: (206) 451-1970
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,950,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -3,176.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,241,106,000
• Free Float: 1,210,078,000
• Market Cap: $248,221.20
• Optionable: Not Optionable
• Beta: 1.22